Clarametyx reports progress on study of antibody therapy CMTX-101 for infections associated with CF, to begin phase 2a portion of the trial

Source :: PharmaBiz. October 19, 2024
Publication Year :: 2024
Abstract: Clarametyx Biosciences, Inc, a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, announced that it has completed the initial phase 1b portion of its [...]

Subjects :: Biopharmaceutics -- Product development
Cystic fibrosis -- Health aspects
Viral antibodies -- Health aspects
Infection -- Health aspects
Clinical trials -- Health aspects
Disease susceptibility -- Health aspects
Antibodies -- Health aspects
Antibiotics -- Product development
Pharmaceuticals and cosmetics industries

Tools